riluzole and Disease Models, Animal studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

Excerpt	Relevance	Reference
"Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease commonly treated with riluzole, a small molecule that may act via modulation of glutamatergic neurotransmission."	8.02	Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. ( Atkin, JD; Berning, BA; Blizzard, CA; Chung, RS; Della Gatta, PA; Gul, H; Hedl, TJ; Jacobs, KR; Keating, SS; Le, S; Lee, A; Mehta, P; Morsch, M; Riddell, WR; San Gil, R; Shi, B; Venturato, J; Walker, AK; Watson, O; Wright, AL, 2021)
"Chronic quinpirole (QNP) sensitization is an established animal model relevant to obsessive-compulsive disorder (OCD) that has been previously shown to induce several OCD-like behavioral patterns, such as compulsive-like checking and increased locomotion."	7.91	No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder. ( Brozka, H; Janikova, M; Radostova, D; Stuchlik, A; Svoboda, J, 2019)
"When used either alone or in combination, both riluzole and resveratrol, two agents with different mechanisms of action in glaucoma, significantly delayed RGC loss in this study's experimental glaucoma model."	7.83	Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma. ( Cengiz, A; Emre, E; Kürşat Yıldız, D; Pirhan, D; Yüksel, N, 2016)
"Systemic (intraperitoneal) application of riluzole (8 mg/kg) inhibited audible (nocifensive response) and ultrasonic (averse affective response) vocalizations of adult rats with arthritis (5 h postinduction of a kaolin-carrageenan monoarthritis in the knee) but did not affect spinal withdrawal thresholds, which is consistent with a supraspinal action."	7.81	Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. ( Ji, G; Neugebauer, V; Thompson, JM, 2015)
"Immediate treatment of spinal root avulsion injuries with minocycline or riluzole prevents the onset of evoked pain hypersensitivity by reducing microglial cell activation."	7.80	The effects of minocycline or riluzole treatment on spinal root avulsion-induced pain in adult rats. ( Carlstedt, T; Chew, DJ; Shortland, PJ, 2014)
"Riluzole and memantine can be safely and effectively delivered intracranially via polymer in rat glioma models."	7.80	Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. ( Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K, 2014)
"Riluzole's therapeutic potential for treating mood disorders may involve GLT-1 and BDNF, and we suggest this protocol could be used to further characterize its precise long-term biochemical mechanisms of action in animal models of depression."	7.78	Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. ( Espitia, JW; Gourley, SL; Sanacora, G; Taylor, JR, 2012)
"The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain."	7.74	A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007)
"The present study examined the effects of riluzole, a Food and Drug Administration-approved drug for amyotrophic lateral sclerosis, on VEGF-stimulated endothelial cell proliferation in culture, and on neovascularization in a rat model of retinopathy of prematurity (ROP)."	7.73	Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. ( Hyun, HJ; Koh, JY; Yoo, MH; Yoon, YH, 2005)
"The effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on the severity of dystonia were examined in mutant hamsters (dtsz), an animal model of idiopathic dystonia in which dystonic attacks can be age dependently induced by mild stress."	7.69	Prodystonic effects of riluzole in an animal model of idiopathic dystonia related to decreased total power in the red nucleus? ( Gernert, M; Löscher, W; Richter, A, 1997)
"Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery."	6.80	Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015)
" This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures."	6.61	Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. ( Jaiswal, MK, 2019)
"Riluzole has been shown to reduce the effects of IRI on various organ systems, but there have yet to be any studies on the effects in IRI of skeletal muscle."	5.56	Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model. ( Chen, M; Deng, Y; Li, RW; Pham, HN; Smith, PN; Weiss, S, 2020)
"Riluzole is a primarily prescribed medicine for ALS patients, while its therapeutical efficacy appears limited."	5.56	Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis. ( Bi, F; Chen, S; Huang, C; Liao, Q; Lu, K; Zhou, J, 2020)
"Riluzole is an antiglutamatergic agent and the only drug to offer some effect on the life expectancy of ALS patients."	5.46	Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam. ( Andreasen, SR; Christensen, TB; Holm, MM; Lundbye, CJ; Schmitt-John, T; Thielsen, KD, 2017)
"Cervical spondylotic myelopathy (CSM) is the commonest cause of spinal cord impairment worldwide and despite surgical treatment, it is commonly associated with chronic neuropathic pain and neurological impairment."	5.40	Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. ( Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR, 2014)
"The riluzole-treated pigs exhibited less myocardial damage than pigs in the control group (65% smaller surface area (P = 0."	5.39	Riluzole reduces arrhythmias and myocardial damage induced by coronary occlusion in anaesthetized pigs. ( Dahlstrom, JE; Saint, DA; Weiss, SM, 2013)
"Riluzole suppression of reactive astrocytosis is an intriguing finding which might contribute to the neuroprotective effects of this drug."	5.38	Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012)
"Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression."	5.36	Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. ( Banasr, M; Behar, KL; Chowdhury, GM; Duman, RS; Newton, SS; Sanacora, G; Terwilliger, R, 2010)
"Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum."	5.33	Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005)
"Acoustic trauma is the major cause of hearing loss in industrialised nations."	5.31	Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. ( Dib, M; Eybalin, M; Hameg, A; Lenoir, M; Puel, JL; Pujol, R; Vago, P; Wang, J, 2002)
"Treatment with riluzole was initiated earlier in the transgenic model than in the human ALS trials, which may account for the significantly better outcome."	5.30	Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. ( Fleck, TJ; Gurney, ME; Hall, ED; Himes, CS, 1998)
"Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease commonly treated with riluzole, a small molecule that may act via modulation of glutamatergic neurotransmission."	4.02	Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. ( Atkin, JD; Berning, BA; Blizzard, CA; Chung, RS; Della Gatta, PA; Gul, H; Hedl, TJ; Jacobs, KR; Keating, SS; Le, S; Lee, A; Mehta, P; Morsch, M; Riddell, WR; San Gil, R; Shi, B; Venturato, J; Walker, AK; Watson, O; Wright, AL, 2021)
"Chronic quinpirole (QNP) sensitization is an established animal model relevant to obsessive-compulsive disorder (OCD) that has been previously shown to induce several OCD-like behavioral patterns, such as compulsive-like checking and increased locomotion."	3.91	No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder. ( Brozka, H; Janikova, M; Radostova, D; Stuchlik, A; Svoboda, J, 2019)
"Riluzole is the most widespread therapeutic for treatment of the progressive degenerative disease amyotrophic lateral sclerosis (ALS)."	3.88	Riluzole does not improve lifespan or motor function in three ALS mouse models. ( Coughlan, KS; Halang, L; Hogg, MC; Prehn, JHM; Woods, I, 2018)
"Compared with the other groups, a statistically significant difference with regard to better results for necrosis, inflammation, and apoptosis was observed in the riluzole only and combination groups."	3.85	Combined and individual use of pancaspase inhibitor Q-VD-OPh and NMDA receptor antagonist riluzole in experimental spinal cord injury. ( Altunrende, ME; Aydoseli, A; Can, H; Dolgun, M; Göker, B; Gömleksiz, C; Sencer, A, 2017)
"When used either alone or in combination, both riluzole and resveratrol, two agents with different mechanisms of action in glaucoma, significantly delayed RGC loss in this study's experimental glaucoma model."	3.83	Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma. ( Cengiz, A; Emre, E; Kürşat Yıldız, D; Pirhan, D; Yüksel, N, 2016)
"Systemic (intraperitoneal) application of riluzole (8 mg/kg) inhibited audible (nocifensive response) and ultrasonic (averse affective response) vocalizations of adult rats with arthritis (5 h postinduction of a kaolin-carrageenan monoarthritis in the knee) but did not affect spinal withdrawal thresholds, which is consistent with a supraspinal action."	3.81	Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. ( Ji, G; Neugebauer, V; Thompson, JM, 2015)
"Riluzole and memantine can be safely and effectively delivered intracranially via polymer in rat glioma models."	3.80	Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. ( Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K, 2014)
"Immediate treatment of spinal root avulsion injuries with minocycline or riluzole prevents the onset of evoked pain hypersensitivity by reducing microglial cell activation."	3.80	The effects of minocycline or riluzole treatment on spinal root avulsion-induced pain in adult rats. ( Carlstedt, T; Chew, DJ; Shortland, PJ, 2014)
" Finally, we investigated its effects on pilocarpine-induced seizures in rats."	3.78	Characterizing the effects of Eugenol on neuronal ionic currents and hyperexcitability. ( Chow, JC; Huang, CW; Tsai, JJ; Wu, SN, 2012)
"Riluzole's therapeutic potential for treating mood disorders may involve GLT-1 and BDNF, and we suggest this protocol could be used to further characterize its precise long-term biochemical mechanisms of action in animal models of depression."	3.78	Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. ( Espitia, JW; Gourley, SL; Sanacora, G; Taylor, JR, 2012)
"Riluzole is the only FDA-approved drug to treat amyotrophic lateral sclerosis, but its long-term effects on motoneurons are unknown."	3.78	Effect of prolonged riluzole exposure on cultured motoneurons in a mouse model of ALS. ( Fu, R; Heckman, CJ; Schuster, JE; Siddique, T, 2012)
"This study tests whether riluzole, a glutamate release inhibitor, and dimethylsulfoxide (DMSO), an anti-inflammatory and antioxidant solvent with favorable properties at the level of glutamate receptors, can protect against early-stage hearing loss in a mouse model of ELH."	3.76	Pharmacological protection of hearing loss in the mouse model of endolymphatic hydrops. ( Alagramam, KN; Frankel, JK; Heddon, CM; Levitt, AH; Megerian, CA; Melki, SJ; Momin, SR, 2010)
" Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with little therapeutics available: riluzole is the only drug approved in its treatment."	3.76	P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. ( Bensimon, G; Buyse, M; Dupuis, L; Farinotti, R; Fernandez, C; Loeffler, JP; Meininger, V; Milane, A, 2010)
"The effects of treatment with the anti-convulsant agents, lamotrigine and riluzole were compared with gabapentin in a rat experimental model of neuropathic pain."	3.74	A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2007)
" In the present study, we compared the effects of riluzole and valproate (VPA) in the pilocarpine-induced limbic seizure model and in the gamma-hydroxybutyrate lactone (GBL)-induced absence seizure model."	3.74	Anti-glutamatergic effect of riluzole: comparison with valproic acid. ( Choi, HC; Choi, SY; Kang, TC; Kim, DS; Kim, JE; Kim, YI; Kwak, SE; Kwon, OS; Song, HK, 2007)
"The present study examined the effects of riluzole, a Food and Drug Administration-approved drug for amyotrophic lateral sclerosis, on VEGF-stimulated endothelial cell proliferation in culture, and on neovascularization in a rat model of retinopathy of prematurity (ROP)."	3.73	Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. ( Hyun, HJ; Koh, JY; Yoo, MH; Yoon, YH, 2005)
"This study investigated the effects of riluzole (Ril), creatine (Cr) and a combination of these treatments on the onset and progression of clinical signs and neuropathology in an animal model of familial amyotrophic lateral sclerosis, the G93A transgenic mouse (n=13-17 per group)."	3.72	Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. ( da Silva, S; Jiang, F; Snow, RJ; Tarnopolsky, MA; Turnbull, J, 2003)
" We examined its neuroprotective effect alone and in combination with the putative glutamate release blocker riluzole in the G93A model of familial amyotrophic lateral sclerosis (fALS)."	3.72	Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. ( Blaugrund, E; Ludolph, AC; Malessa, S; Reuter, A; Waibel, S, 2004)
" Experimental groups were as follows: sham operation group (n = 5), control group undergoing occlusion but receiving no pharmacologic intervention (n = 10), experimental group A (n = 10) receiving 8 mg/kg riluzole intravenously 30 minutes before ischemia, experimental group B (n = 10) receiving 4 mg/kg riluzole intravenously 30 minutes before ischemia and at the onset of reperfusion, and experimental group C (n = 10) receiving 8 mg/kg riluzole intravenously at the onset of reperfusion."	3.70	Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping. ( Heurteaux, C; Lang-Lazdunski, L; Lazdunski, M; Vaillant, N; Widmann, C, 1999)
"The effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on the severity of dystonia were examined in mutant hamsters (dtsz), an animal model of idiopathic dystonia in which dystonic attacks can be age dependently induced by mild stress."	3.69	Prodystonic effects of riluzole in an animal model of idiopathic dystonia related to decreased total power in the red nucleus? ( Gernert, M; Löscher, W; Richter, A, 1997)
"Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery."	2.80	Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015)
" This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures."	2.61	Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. ( Jaiswal, MK, 2019)
" This may be due to fundamental differences between rodent models and human disease, the fact that animal models are based on overexpression of mutated genes, and confounding issues such as difficulties mimicking the dosing schedules and regimens implemented in mouse models to humans."	2.53	Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. ( Moujalled, D; White, AR, 2016)
"A wide variety of models of Huntington's disease have been developed including yeast, Caenorhabditis elegans, Drosophila melanogaster and mouse."	2.42	Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? ( Bates, GP; Hockly, E, 2003)
"Riluzole has been shown to reduce the effects of IRI on various organ systems, but there have yet to be any studies on the effects in IRI of skeletal muscle."	1.56	Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model. ( Chen, M; Deng, Y; Li, RW; Pham, HN; Smith, PN; Weiss, S, 2020)
"Riluzole is a primarily prescribed medicine for ALS patients, while its therapeutical efficacy appears limited."	1.56	Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis. ( Bi, F; Chen, S; Huang, C; Liao, Q; Lu, K; Zhou, J, 2020)
"Riluzole treatment is more effective when provided before injury."	1.48	Effect of Riluzole on Spinal Cord Regeneration with Hemisection Method Before Injury. ( Al-Beyati, ESM; Bahadir, B; Caglar, YS; Cansiz, C; Demirel, A; Dogan, I; Eroglu, U; Huseynov, R; Kilinc, MC; Ozgural, O, 2018)
"Chronic neuropathic pain is an important healthcare issue with significant emotional components."	1.48	Small conductance calcium activated potassium (SK) channel dependent and independent effects of riluzole on neuropathic pain-related amygdala activity and behaviors in rats. ( Ji, G; Neugebauer, V; Thompson, JM; Yakhnitsa, V, 2018)
"Riluzole is an antiglutamatergic agent and the only drug to offer some effect on the life expectancy of ALS patients."	1.46	Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam. ( Andreasen, SR; Christensen, TB; Holm, MM; Lundbye, CJ; Schmitt-John, T; Thielsen, KD, 2017)
"Riluzole is known to increase the glutamate transporter EAAT2's ability to scavenge excess glutamate, regulating synaptic transmission."	1.46	Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole. ( Davidson, RL; Gray, JD; Kogan, JF; McEwen, BS; Morrison, JH; Okamoto, M; Pereira, AC; Rubin, TG, 2017)
"Treatment with riluzole restored glutamate regulation and rescued memory deficits in the TauP301L model."	1.43	Riluzole rescues alterations in rapid glutamate transients in the hippocampus of rTg4510 mice. ( Hickman, JE; Hunsberger, HC; Reed, MN, 2016)
" SKA-19 is orally bioavailable and shows activity in a broad range of rodent seizure models."	1.42	The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. ( Brown, BM; Cao, Z; Chen, YJ; Coleman, N; Goldin, AL; Jenkins, DP; Nguyen, HM; Pessah, IN; Rogawski, MA; Tanaka, BS; Wulff, H; Zolkowska, D, 2015)
"Cervical spondylotic myelopathy (CSM) is the commonest cause of spinal cord impairment worldwide and despite surgical treatment, it is commonly associated with chronic neuropathic pain and neurological impairment."	1.40	Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. ( Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR, 2014)
"The riluzole-treated pigs exhibited less myocardial damage than pigs in the control group (65% smaller surface area (P = 0."	1.39	Riluzole reduces arrhythmias and myocardial damage induced by coronary occlusion in anaesthetized pigs. ( Dahlstrom, JE; Saint, DA; Weiss, SM, 2013)
" We found that licofelone both reduced Pgp expression and enhanced riluzole bioavailability within the lesion site at 72 h post-SCI."	1.39	The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord. ( Dulin, JN; Grill, RJ; Moore, ML, 2013)
"Spinocerebellar ataxias are autosomal dominant diseases, associated in some types with a CAG repeat expansion, and characterised by a progressive loss of motor function."	1.39	Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1. ( Nag, N; Storey, E; Tarlac, V, 2013)
"Riluzole is a pleotropic drug that blocks "persistent sodium currents" in neurons, but in SCI, its molecular mechanism of action is uncertain."	1.38	Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. ( Gerzanich, V; Ivanov, A; Ivanova, S; Keledjian, K; Simard, JM; Tsymbalyuk, O, 2012)
"Riluzole suppression of reactive astrocytosis is an intriguing finding which might contribute to the neuroprotective effects of this drug."	1.38	Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. ( Carbone, M; Duty, S; Rattray, M, 2012)
" We examined the possibility that concurrent blockade of free radicals and prostaglandin E(2) (PGE(2))-mediated inflammation might constitute a safe and effective therapeutic approach to ALS."	1.38	Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. ( Cho, W; Gwag, BJ; Im, DS; Lee, JH; Lee, JK; Lee, YA; Lee, YB; Shin, JH; Springer, JE; Yun, BS, 2012)
"Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression."	1.36	Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. ( Banasr, M; Behar, KL; Chowdhury, GM; Duman, RS; Newton, SS; Sanacora, G; Terwilliger, R, 2010)
"Riluzole promoted increase and/or preservation of axon density in the animals treated with this drug as compared to the control group; it did not increase the mean diameter of facial nerve fibres as compared to the non-treated group; and it did not provide a better functional motor recovery than in the control group."	1.34	Evaluation of the systemic use of riluzole in post-traumatic facial nerve regeneration: experimental study in rabbits. ( Costa, HJ; Costa, MP; da Silva, CF; Lazarini, PR, 2007)
"Riluzole is a Food and Drug Administration-approved anti-ALS drug with a favorable adverse effect profile."	1.34	Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: inhibition by riluzole. ( Cho, KS; Chung, H; Koh, JY; Yoo, MH; Yoon, YH, 2007)
"Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum."	1.33	Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005)
"Pretreatment with riluzole 10 mg/kg, but not 3 mg/kg, had a moderately depressant effect both on spontaneous and amphetamine-induced locomotion."	1.32	Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. ( Dall'Igna, OP; Dietrich, MO; Hoffmann, A; Lara, DR; Lourenço Da Silva, A; Souza, DO, 2003)
"Riluzole, has previously been shown to be protective in animal models of Parkinson's disease in vivo."	1.31	The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. ( Boireau, A; Bordier, F; Dubedat, P; Imperato, A; Moussaoui, S, 2000)
" However, the dosage used in animal experiments was much higher than that in human."	1.31	Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia. ( Bae, HJ; Gu, JS; Kang, DW; Koo, JS; Lee, YS; Roh, JK; Yoon, BW, 2000)
"Temporary spinal cord ischemia was induced by 29 min of infrarenal balloon occlusion of the aorta in 60 anesthetized New Zealand white rabbits."	1.31	Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. ( Bodewits, P; de Haan, P; Dzoljic, M; Jacobs, MJ; Kalkman, CJ; Lips, J; Vanicky, I, 2000)
"Acoustic trauma is the major cause of hearing loss in industrialised nations."	1.31	Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. ( Dib, M; Eybalin, M; Hameg, A; Lenoir, M; Puel, JL; Pujol, R; Vago, P; Wang, J, 2002)
"In these animals, as in Parkinson's disease, dopaminergic neurons of the nigro-striatal pathway undergo spontaneous and progressive cell death."	1.31	Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice. ( Agid, Y; Blanchard, V; Bohme, GA; Debeir, T; Do, L; Douhou, A; Dufour, N; Moussaoui, S; Murer, MG; Raisman-Vozari, R, 2002)
"Treatment with riluzole was initiated earlier in the transgenic model than in the human ALS trials, which may account for the significantly better outcome."	1.30	Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. ( Fleck, TJ; Gurney, ME; Hall, ED; Himes, CS, 1998)
"Riluzole treatment beyond 1 h (e."	1.30	Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome. ( Hall, ED; Smith, SL, 1998)
"Posthypoxic myoclonus and seizures precipitate as secondary neurological consequences in ischemic/hypoxic insults of the central nervous system."	1.30	Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. ( Kanthasamy, AG; Nguyen, B; Truong, DD; Yun, RJ, 1999)

Research

Studies (125)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Montgomery-Asberg Depression Rating Scale

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	11 (8.80)	18.2507
2000's	46 (36.80)	29.6817
2010's	60 (48.00)	24.3611
2020's	8 (6.40)	2.80

Authors	Studies
Solinski, HJ	1
Dranchak, P	1
Oliphant, E	1
Gu, X	1
Earnest, TW	1
Braisted, J	1
Inglese, J	1
Hoon, MA	1
Abrams, RPM	1
Yasgar, A	1
Teramoto, T	1
Lee, MH	1
Dorjsuren, D	1
Eastman, RT	1
Malik, N	1
Zakharov, AV	1
Li, W	2
Bachani, M	1
Brimacombe, K	1
Steiner, JP	1
Hall, MD	1
Balasubramanian, A	1
Jadhav, A	1
Padmanabhan, R	1
Simeonov, A	1
Nath, A	1
Cougnoux, A	1
Yerger, JC	1
Fellmeth, M	1
Serra-Vinardell, J	1
Navid, F	1
Wassif, CA	1
Cawley, NX	1
Porter, FD	1
Saba, K	1
Patel, AB	1
Findley, CA	1
McFadden, SA	1
Cox, MF	1
Sime, LN	1
Peck, MR	1
Quinn, K	1
Bartke, A	1
Hascup, KN	1
Hascup, ER	1
Li, RW	1
Deng, Y	1
Pham, HN	1
Weiss, S	1
Chen, M	1
Smith, PN	1
Chen, S	3
Liao, Q	1
Lu, K	1
Zhou, J	1
Huang, C	1
Bi, F	1
Janikova, M	2
Mainerova, K	1
Vojtechova, I	1
Petrasek, T	1
Svoboda, J	2
Stuchlik, A	2
Wright, AL	1
Della Gatta, PA	1
Le, S	1
Berning, BA	1
Mehta, P	1
Jacobs, KR	1
Gul, H	1
San Gil, R	1
Hedl, TJ	1
Riddell, WR	1
Watson, O	1
Keating, SS	1
Venturato, J	1
Chung, RS	1
Atkin, JD	1
Lee, A	1
Shi, B	1
Blizzard, CA	1
Morsch, M	1
Walker, AK	1
Jimenez-Pacheco, A	1
Franco, JM	1
Lopez, S	1
Gomez-Zumaquero, JM	1
Magdalena Leal-Lasarte, M	1
Caballero-Hernandez, DE	1
Cejudo-Guillén, M	1
Pozo, D	1
Wangpaichitr, M	1
Wu, C	1
Li, YY	1
Nguyen, DJM	1
Kandemir, H	1
Shah, S	1
Feun, LG	1
Prince, JS	1
Kuo, MT	1
Savaraj, N	1
Rizzo, F	1
Abaei, A	1
Nespoli, E	2
Fegert, JM	1
Hengerer, B	2
Rasche, V	1
Boeckers, TM	1
Andreasen, SR	1
Lundbye, CJ	1
Christensen, TB	1
Thielsen, KD	1
Schmitt-John, T	1
Holm, MM	1
Yamamoto, S	1
Ushio, S	1
Egashira, N	1
Kawashiri, T	1
Mitsuyasu, S	1
Higuchi, H	1
Ozawa, N	1
Masuguchi, K	1
Ono, Y	1
Masuda, S	1
Can, H	1
Aydoseli, A	1
Gömleksiz, C	1
Göker, B	1
Altunrende, ME	1
Dolgun, M	1
Sencer, A	1
Hogg, MC	1
Halang, L	1
Woods, I	1
Coughlan, KS	1
Prehn, JHM	1
Caglar, YS	1
Demirel, A	1
Dogan, I	1
Huseynov, R	1
Eroglu, U	1
Ozgural, O	1
Cansiz, C	1
Bahadir, B	1
Kilinc, MC	1
Al-Beyati, ESM	1
Thompson, JM	2
Yakhnitsa, V	1
Ji, G	2
Neugebauer, V	2
Jaiswal, MK	1
Okamoto, M	2
Gray, JD	2
Larson, CS	1
Kazim, SF	1
Soya, H	1
McEwen, BS	2
Pereira, AC	2
Zhu, Y	1
Gao, M	1
Zhou, T	1
Xie, M	1
Mao, A	1
Feng, L	1
Yao, X	1
Wong, WT	1
Ma, X	1
Pagliaroli, L	1
Widomska, J	1
Hildebrandt, T	1
Barta, C	1
Glennon, J	2
Poelmans, G	1
Brozka, H	1
Radostova, D	1
Ikenaka, K	1
Tsukada, Y	1
Giles, AC	1
Arai, T	1
Nakadera, Y	1
Nakano, S	1
Kawai, K	1
Mochizuki, H	1
Katsuno, M	1
Sobue, G	1
Mori, I	1
Chapela, D	1
Sousa, S	1
Martins, I	1
Cristóvão, AM	1
Pinto, P	1
Corte-Real, S	1
Saúde, L	1
Wu, Y	1
Satkunendrarajah, K	1
Teng, Y	1
Chow, DS	1
Buttigieg, J	1
Fehlings, MG	5
Dimitriadi, M	1
Kye, MJ	1
Kalloo, G	1
Yersak, JM	1
Sahin, M	1
Hart, AC	1
Li, J	1
Sung, M	1
Rutkove, SB	1
Pandya, RS	1
Zhu, H	1
Bowser, R	1
Friedlander, RM	1
Wang, X	1
Moon, ES	1
Karadimas, SK	2
Yu, WR	1
Austin, JW	1
Weiss, SM	1
Dahlstrom, JE	1
Saint, DA	1
Yohay, K	1
Tyler, B	1
Weaver, KD	1
Pardo, AC	1
Gincel, D	1
Blakeley, J	1
Brem, H	1
Rothstein, JD	1
Desaphy, JF	1
Carbonara, R	1
Costanza, T	1
Conte Camerino, D	1
Chew, DJ	1
Carlstedt, T	2
Shortland, PJ	3
Yacila, G	1
Sari, Y	1
Pronto-Laborinho, AC	1
Pinto, S	1
de Carvalho, M	1
Coleman, N	1
Nguyen, HM	1
Cao, Z	1
Brown, BM	1
Jenkins, DP	1
Zolkowska, D	1
Chen, YJ	1
Tanaka, BS	1
Goldin, AL	1
Rogawski, MA	1
Pessah, IN	1
Wulff, H	1
Ittner, AA	1
Gladbach, A	1
Bertz, J	1
Suh, LS	1
Ittner, LM	1
Wall, BA	1
Yu, LJ	1
Khan, A	1
Haffty, B	1
Goydos, JS	1
Pirhan, D	1
Yüksel, N	1
Emre, E	1
Cengiz, A	1
Kürşat Yıldız, D	1
O'Connor, RM	1
Moloney, RD	1
Vlachou, S	1
Cryan, JF	1
Hosier, H	1
Peterson, D	1
Tsymbalyuk, O	2
Keledjian, K	2
Smith, BR	1
Ivanova, S	2
Gerzanich, V	2
Popovich, PG	1
Simard, JM	2
Laliberte, AM	1
Tetreault, L	1
Chung, YS	1
Arnold, P	1
Foltz, WD	1
Hunsberger, HC	1
Hickman, JE	1
Reed, MN	1
Moujalled, D	1
White, AR	1
Schmidt, J	1
Schmidt, T	1
Golla, M	1
Lehmann, L	1
Weber, JJ	1
Hübener-Schmid, J	1
Riess, O	1
Kogan, JF	1
Davidson, RL	1
Rubin, TG	1
Morrison, JH	1
Benedetti, L	1
Ghilardi, A	1
Rottoli, E	1
De Maglie, M	1
Prosperi, L	1
Perego, C	1
Baruscotti, M	1
Bucchi, A	1
Del Giacco, L	1
Francolini, M	1
Ghayour, MB	1
Abdolmaleki, A	1
Behnam-Rassouli, M	1
Boucherie, C	1
Caumont, AS	1
Maloteaux, JM	1
Hermans, E	1
Banasr, M	1
Chowdhury, GM	1
Terwilliger, R	1
Newton, SS	1
Duman, RS	1
Behar, KL	1
Sanacora, G	4
Aziz, NA	1
van der Burg, JM	1
Landwehrmeyer, GB	1
Brundin, P	1
Stijnen, T	1
Roos, RA	1
Pieri, M	1
Carunchio, I	1
Curcio, L	1
Mercuri, NB	1
Zona, C	1
Valentine, GW	1
Fong, AY	1
Marshall, LH	1
Milsom, WK	1
Danesh-Meyer, HV	1
Levin, LA	1
Brunet, N	1
Tarabal, O	1
Esquerda, JE	1
Calderó, J	1
Pambo-Pambo, A	2
Durand, J	2
Gueritaud, JP	2
Milane, A	1
Fernandez, C	1
Dupuis, L	1
Buyse, M	1
Loeffler, JP	1
Farinotti, R	1
Meininger, V	1
Bensimon, G	1
Takahashi, K	1
Murasawa, H	1
Yamaguchi, K	1
Yamada, M	2
Nakatani, A	1
Yoshida, M	1
Iwai, T	1
Inagaki, M	1
Saitoh, A	1
Melki, SJ	1
Heddon, CM	1
Frankel, JK	1
Levitt, AH	1
Momin, SR	1
Alagramam, KN	1
Megerian, CA	1
Cadotte, DW	1
Gourley, SL	1
Espitia, JW	1
Taylor, JR	1
Hobo, S	1
Eisenach, JC	1
Hayashida, K	1
Schuster, JE	1
Fu, R	1
Siddique, T	1
Heckman, CJ	1
Huang, CW	1
Chow, JC	1
Tsai, JJ	1
Wu, SN	1
Ivanov, A	1
Carbone, M	1
Duty, S	1
Rattray, M	1
Shin, JH	1
Lee, YA	1
Lee, JK	1
Lee, YB	1
Cho, W	1
Im, DS	1
Lee, JH	1
Yun, BS	1
Springer, JE	1
Gwag, BJ	1
Nag, N	1
Tarlac, V	1
Storey, E	1
Jung, HH	1
Neumann, M	1
Bloch, KE	1
Dulin, JN	1
Moore, ML	1
Grill, RJ	1
Linden, DR	1
Tator, CH	1
Hashimoto, R	1
Raich, A	1
Norvell, D	1
Harrop, JS	1
Guest, J	1
Aarabi, B	1
Grossman, RG	1
McGown, A	1
McDearmid, JR	1
Panagiotaki, N	1
Tong, H	1
Al Mashhadi, S	1
Redhead, N	1
Lyon, AN	1
Beattie, CE	1
Shaw, PJ	1
Ramesh, TM	1
Pascuzzi, RM	1
Cepeda, C	1
Hurst, RS	1
Calvert, CR	1
Hernández-Echeagaray, E	1
Nguyen, OK	1
Jocoy, E	1
Christian, LJ	1
Ariano, MA	1
Levine, MS	1
Dunlop, J	1
Beal McIlvain, H	1
She, Y	1
Howland, DS	1
Kriz, J	1
Gowing, G	1
Julien, JP	1
Snow, RJ	1
Turnbull, J	1
da Silva, S	1
Jiang, F	1
Tarnopolsky, MA	1
Gilgun-Sherki, Y	2
Melamed, E	2
Ziv, I	1
Offen, D	2
Bates, GP	2
Hockly, E	2
Lourenço Da Silva, A	1
Hoffmann, A	1
Dietrich, MO	1
Dall'Igna, OP	1
Souza, DO	1
Lara, DR	1
Panet, H	1
Bergerot, A	1
Anand, P	1
Hunt, SP	1
Guitton, MJ	1
Wang, J	2
Puel, JL	2
Waibel, S	1
Reuter, A	1
Malessa, S	1
Blaugrund, E	1
Ludolph, AC	2
Kunst, CB	1
Borowicz, KK	1
Rwiader, M	1
Drelewska, E	1
Czuczwar, SJ	1
Scherfler, C	1
Sather, T	1
Diguet, E	1
Stefanova, N	1
Puschban, Z	1
Tison, F	1
Poewe, W	1
Wenning, GK	1
Lundblad, M	1
Usiello, A	1
Carta, M	1
Håkansson, K	1
Fisone, G	1
Cenci, MA	1
Tse, J	1
Barker, AL	1
Moolman, DL	1
Beunard, JL	1
Revington, AP	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471]	Phase 3	400 participants (Anticipated)	Interventional	2021-12-22	Recruiting
Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance[NCT01879241]	Phase 2	252 participants (Actual)	Interventional	2013-06-30	Completed
Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V.[NCT00500396]	Phase 4	15 participants (Anticipated)	Interventional	2007-03-31	Completed
Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V[NCT00563121]	Phase 4	16 participants (Actual)	Interventional	2007-03-31	Completed
Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154]		200 participants (Anticipated)	Observational	2008-11-30	Not yet recruiting
An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression[NCT00054704]	Phase 2	19 participants (Actual)	Interventional	2003-02-28	Terminated (stopped due to Placebo was better than active drug.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician-rated assessment of depression symptoms. Patients were rated weekly on 10 symptoms on a scale of 0 to 6 for each item, where 0 indicated no symptoms and 6 indicated the highest severity of that symptom. Total scores range from 0 to 60, where a moderate severity of depression would be present with a score of at least 20. (NCT00054704)
Timeframe: 8 weeks

Article	Year
Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis. Advances in experimental medicine and biology, 2017, Volume: 978 Topics: Acetylation; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA Methylation; Enviro	2017
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Medicinal research reviews, 2019, Volume: 39, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Clinical Trials as Topic; Disease Models, Anim	2019
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cellular and molecular life sciences : CMLS, 2013, Volume: 70, Issue:24 Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Disease M	2013
Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis. BioMed research international, 2014, Volume: 2014 Topics: Amyotrophic Lateral Sclerosis; Animals; Axons; Brain Stem; Cell Movement; Disease Models, Animal; Hu	2014
Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. CNS drugs, 2016, Volume: 30, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; H	2016
Neuroprotection: extrapolating from neurologic diseases to the eye. American journal of ophthalmology, 2009, Volume: 148, Issue:2 Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Endpoint Determination; Excitatory Amino	2009
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10 Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Drug Design; Hum	2009
Spinal cord injury: a systematic review of current treatment options. Clinical orthopaedics and related research, 2011, Volume: 469, Issue:3 Topics: Animals; Decompression, Surgical; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Inhib	2011
[Amyotrophic lateral sclerosis--diagnosis and treatment]. Praxis, 2012, Jul-04, Volume: 101, Issue:14 Topics: Activities of Daily Living; Aged; Amyotrophic Lateral Sclerosis; Animals; Cause of Death; Cross-Sect	2012
Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury. Journal of neurosurgery. Spine, 2012, Volume: 17, Issue:1 Suppl Topics: Animals; Disease Models, Animal; Glyburide; Humans; Magnesium Sulfate; Minocycline; Neuroprotective	2012
ALS, motor neuron disease, and related disorders: a personal approach to diagnosis and management. Seminars in neurology, 2002, Volume: 22, Issue:1 Topics: Adolescent; Adult; Animals; Case Management; Combined Modality Therapy; Creatine; Diagnosis, Differe	2002
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Current opinion in neurology, 2003, Volume: 16, Issue:4 Topics: Acetamides; Animals; Antioxidants; Creatine; Disease Models, Animal; Evaluation Studies as Topic; Hu	2003
Complex genetics of amyotrophic lateral sclerosis. American journal of human genetics, 2004, Volume: 75, Issue:6 Topics: Amino Acid Transport System X-AG; Amyotrophic Lateral Sclerosis; Animals; Apolipoproteins E; Ciliary	2004
[Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms]. Der Nervenarzt, 2008, Volume: 79, Issue:6 Topics: Amyotrophic Lateral Sclerosis; Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Evalu	2008
Sodium and potassium channel modulators: their role in neuroprotection. International review of neurobiology, 1997, Volume: 40 Topics: Animals; Benzeneacetamides; Cell Survival; Disease Models, Animal; Lamotrigine; Neurons; Neuroprotec	1997
Treatment of amyotrophic lateral sclerosis--what is the next step? Journal of neurology, 2000, Volume: 247 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; H	2000
Therapies in amyotrophic lateral sclerosis-beyond riluzole. Current opinion in pharmacology, 2002, Volume: 2, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Hypoxia; Disease Models, Animal; Humans; Neuroprotectiv	2002

Article	Year
Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. Science translational medicine, 2015, Dec-02, Volume: 7, Issue:316 Topics: Animals; Axons; Cervical Vertebrae; Decompression, Surgical; Disease Models, Animal; Humans; Magneti	2015
Weight loss in Huntington disease increases with higher CAG repeat number. Neurology, 2008, Nov-04, Volume: 71, Issue:19 Topics: Adult; Aged; Animals; Body Mass Index; Body Weight; Disease Models, Animal; Energy Intake; Female; H	2008

Article	Year
Inhibition of natriuretic peptide receptor 1 reduces itch in mice. Science translational medicine, 2019, 07-10, Volume: 11, Issue:500 Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S	2019
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr	2020
Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1. Molecular genetics and metabolism, 2021, Volume: 134, Issue:4 Topics: Animals; Astrocytes; Ceftriaxone; Cells, Cultured; Disease Models, Animal; Excitatory Amino Acid Tra	2021
Riluzole restores memory and brain energy metabolism in AβPP-PS1 mouse model of Alzheimer's disease. Biochemical and biophysical research communications, 2022, 06-25, Volume: 610 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Disease Models, Animal; Energy Me	2022
Prodromal Glutamatergic Modulation with Riluzole Impacts Glucose Homeostasis and Spatial Cognition in Alzheimer's Disease Mice. Journal of Alzheimer's disease : JAD, 2023, Volume: 94, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition; Diseas	2023
Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model. Injury, 2020, Volume: 51, Issue:2 Topics: Animals; Apoptosis; Disease Models, Animal; Muscle, Skeletal; Random Allocation; Reperfusion Injury;	2020
Riluzole Exhibits No Therapeutic Efficacy on a Transgenic Rat model of Amyotrophic Lateral Sclerosis. Current neurovascular research, 2020, Volume: 17, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA-Binding Proteins; Humans; Neurop	2020
Memantine and Riluzole Exacerbate, Rather Than Ameliorate Behavioral Deficits Induced by 8-OH-DPAT Sensitization in a Spatial Task. Biomolecules, 2021, 07-09, Volume: 11, Issue:7 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Male; Mem	2021
Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. The European journal of neuroscience, 2021, Volume: 54, Issue:6 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA-Binding Proteins; Female; Mice;	2021
Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. Oncotarget, 2017, Jul-25, Volume: 8, Issue:30 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Disease Models, Animal;	2017
Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal Translational psychiatry, 2017, 08-01, Volume: 7, Issue:8 Topics: Animals; Antipsychotic Agents; Aripiprazole; Aspartic Acid; Attention Deficit Disorder with Hyperact	2017
Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam. Neuroscience letters, 2017, Sep-29, Volume: 658 Topics: Amyotrophic Lateral Sclerosis; Animals; Diazepam; Disease Models, Animal; Hippocampus; Mice, Inbred	2017
Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. Scientific reports, 2017, 08-29, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Agents; Biological Transport; Chemoprevention; Disease Models, Animal; Excit	2017
Combined and individual use of pancaspase inhibitor Q-VD-OPh and NMDA receptor antagonist riluzole in experimental spinal cord injury. Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2017, Volume: 23, Issue:6 Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Disease Models, Animal; Male; Necrosis; Neuropr	2017
Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotrophic lateral sclerosis & frontotemporal degeneration, 2018, Volume: 19, Issue:5-6 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progression; DNA-Binding Pro	2018
Effect of Riluzole on Spinal Cord Regeneration with Hemisection Method Before Injury. World neurosurgery, 2018, Volume: 114 Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Lam	2018
Small conductance calcium activated potassium (SK) channel dependent and independent effects of riluzole on neuropathic pain-related amygdala activity and behaviors in rats. Neuropharmacology, 2018, Volume: 138 Topics: Analgesics, Non-Narcotic; Animals; Central Amygdaloid Nucleus; Disease Models, Animal; Male; Membran	2018
Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer's disease. Translational psychiatry, 2018, 08-14, Volume: 8, Issue:1 Topics: Alzheimer Disease; Animals; Astrocytes; Cognition; Disease Models, Animal; Gene Expression; Hippocam	2018
The TRPC5 channel regulates angiogenesis and promotes recovery from ischemic injury in mice. The Journal of biological chemistry, 2019, 01-04, Volume: 294, Issue:1 Topics: Animals; Disease Models, Animal; Endothelial Cells; HEK293 Cells; Humans; Ischemia; Mice; Mice, Knoc	2019
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model. Molecular neurobiology, 2019, Volume: 56, Issue:7 Topics: Animals; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dyskinesia, Drug-Induc	2019
No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder. Physiology & behavior, 2019, 05-15, Volume: 204 Topics: Animals; Behavior, Animal; Cognition; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Ac	2019
A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease. Scientific reports, 2019, 07-12, Volume: 9, Issue:1 Topics: Amyotrophic Lateral Sclerosis; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dis	2019
A zebrafish drug screening platform boosts the discovery of novel therapeutics for spinal cord injury in mammals. Scientific reports, 2019, 07-19, Volume: 9, Issue:1 Topics: Animals; Cycloserine; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Female;	2019
Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. Journal of neurotrauma, 2013, Mar-15, Volume: 30, Issue:6 Topics: Animals; Cervical Vertebrae; Disease Models, Animal; Drug Evaluation, Preclinical; Evoked Potentials	2013
The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Apr-10, Volume: 33, Issue:15 Topics: Animals; Axons; Caenorhabditis elegans; Cells, Cultured; Disease Models, Animal; Gene Knockdown Tech	2013
Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice. PloS one, 2013, Volume: 8, Issue:6 Topics: Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Models, Animal;	2013
Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. Neurobiology of disease, 2014, Volume: 62 Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Gait; Hyperalgesia; Neur	2014
Riluzole reduces arrhythmias and myocardial damage induced by coronary occlusion in anaesthetized pigs. Clinical and experimental pharmacology & physiology, 2013, Volume: 40, Issue:12 Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Occlusion; Disease Models, Animal; E	2013
Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. Journal of neurosurgery, 2014, Volume: 120, Issue:4 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Excitator	2014
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs. Experimental neurology, 2014, Volume: 255 Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle	2014
The effects of minocycline or riluzole treatment on spinal root avulsion-induced pain in adult rats. The journal of pain, 2014, Volume: 15, Issue:6 Topics: Animals; Disease Models, Animal; Functional Laterality; Hyperalgesia; Male; Minocycline; Neurons; Ne	2014
Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis. Current medicinal chemistry, 2014, Volume: 21, Issue:31 Topics: Amyotrophic Lateral Sclerosis; Animals; Anticonvulsants; Biomarkers; Cell- and Tissue-Based Therapy;	2014
The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2015, Volume: 12, Issue:1 Topics: Animals; Anticonvulsants; Disease Models, Animal; Male; Mice; Pain Threshold; Rats; Rats, Sprague-Da	2015
p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimer's disease. Acta neuropathologica communications, 2014, Oct-21, Volume: 2 Topics: Alzheimer Disease; Animals; Disease Models, Animal; Dizocilpine Maleate; Electrodes, Implanted; Elec	2014
Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells. Pigment cell & melanoma research, 2015, Volume: 28, Issue:1 Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Clone Cells; Disease Models, Animal; Humans; Luciferases	2015
Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma. Current eye research, 2016, Volume: 41, Issue:1 Topics: Animals; Antioxidants; Cell Count; Cell Survival; Disease Models, Animal; Drug Therapy, Combination;	2016
Enhancing glutamatergic transmission during adolescence reverses early-life stress-induced deficits in the rewarding effects of cocaine in rats. Neuropharmacology, 2015, Volume: 99 Topics: Administration, Intravenous; Aging; Amino Acid Transport System X-AG; Animals; Cocaine; Cocaine-Rela	2015
A Direct Comparison of Three Clinically Relevant Treatments in a Rat Model of Cervical Spinal Cord Injury. Journal of neurotrauma, 2015, Nov-01, Volume: 32, Issue:21 Topics: Animals; Behavior, Animal; Cervical Cord; Disease Models, Animal; Female; Glyburide; Hypoglycemic Ag	2015
Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Molecular pain, 2015, Aug-28, Volume: 11 Topics: Amygdala; Animals; Arthritis; Disease Models, Animal; Hindlimb; Male; Microdialysis; Pain; Rats, Spr	2015
Riluzole rescues alterations in rapid glutamate transients in the hippocampus of rTg4510 mice. Metabolic brain disease, 2016, Volume: 31, Issue:3 Topics: Alzheimer Disease; Animals; Disease Models, Animal; Glutamic Acid; Hippocampus; Memory Disorders; Mi	2016
In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3. Journal of neurochemistry, 2016, Volume: 138, Issue:1 Topics: Animals; Ataxin-3; Body Weight; Brain; Calbindins; Disease Models, Animal; Fluorescence Resonance En	2016
Age and Alzheimer's disease gene expression profiles reversed by the glutamate modulator riluzole. Molecular psychiatry, 2017, Volume: 22, Issue:2 Topics: Age Factors; Aging; Alzheimer Disease; Animals; Cognition; Cognitive Aging; Disease Models, Animal;	2017
INaP selective inhibition reverts precocious inter- and motorneurons hyperexcitability in the Sod1-G93R zebrafish ALS model. Scientific reports, 2016, Apr-15, Volume: 6 Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Disease Mo	2016
The effect of Riluzole on functional recovery of locomotion in the rat sciatic nerve crush model. European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2017, Volume: 43, Issue:5 Topics: Animals; Crush Injuries; Disease Models, Animal; Injections, Intraperitoneal; Locomotion; Male; Nerv	2017
In vitro evidence for impaired neuroprotective capacities of adult mesenchymal stem cells derived from a rat model of familial amyotrophic lateral sclerosis (hSOD1(G93A)). Experimental neurology, 2008, Volume: 212, Issue:2 Topics: Amino Acid Transport System X-AG; Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modif	2008
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular psychiatry, 2010, Volume: 15, Issue:5 Topics: Acetates; Animals; Avoidance Learning; Behavioral Symptoms; Depression; Disease Models, Animal; Food	2010
Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Experimental neurology, 2009, Volume: 215, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Animals; Biophysical Phenomena; Cells, Cultured; Cerebral Cortex; Dis	2009
Targeting glial physiology and glutamate cycling in the treatment of depression. Biochemical pharmacology, 2009, Sep-01, Volume: 78, Issue:5 Topics: Animals; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Glutamic Acid; Human	2009
Riluzole disrupts autoresuscitation from hypothermic respiratory arrest in neonatal hamsters but not rats. Respiratory physiology & neurobiology, 2009, May-15, Volume: 166, Issue:3 Topics: Action Potentials; Age Factors; Analysis of Variance; Animals; Animals, Newborn; Brain Stem; Criceti	2009
Excitotoxic motoneuron degeneration induced by glutamate receptor agonists and mitochondrial toxins in organotypic cultures of chick embryo spinal cord. The Journal of comparative neurology, 2009, Oct-01, Volume: 516, Issue:4 Topics: Animals; Calcium Signaling; Chick Embryo; Disease Models, Animal; Dose-Response Relationship, Drug;	2009
Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G(93A-Low) mice. Journal of neurophysiology, 2009, Volume: 102, Issue:6 Topics: Amyotrophic Lateral Sclerosis; Animals; Arginine; Biophysical Phenomena; Biophysics; Calcium Channel	2009
P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neuroscience letters, 2010, Mar-26, Volume: 472, Issue:3 Topics: Amyotrophic Lateral Sclerosis; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP	2010
Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression. Behavioural brain research, 2011, Jan-01, Volume: 216, Issue:1 Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Depressive Di	2011
Pharmacological protection of hearing loss in the mouse model of endolymphatic hydrops. The Laryngoscope, 2010, Volume: 120, Issue:8 Topics: Animals; Dimethyl Sulfoxide; Disease Models, Animal; Endolymphatic Hydrops; Hearing Loss; Mice; Neur	2010
Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology, 2012, Volume: 219, Issue:3 Topics: Administration, Oral; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression;	2012
Up-regulation of spinal glutamate transporters contributes to anti-hypersensitive effects of valproate in rats after peripheral nerve injury. Neuroscience letters, 2011, Sep-08, Volume: 502, Issue:1 Topics: Analgesics; Animals; Disease Models, Animal; Drug Therapy, Combination; Excitatory Amino Acid Transp	2011
Effect of prolonged riluzole exposure on cultured motoneurons in a mouse model of ALS. Journal of neurophysiology, 2012, Volume: 107, Issue:1 Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Disease Models, Animal;	2012
Characterizing the effects of Eugenol on neuronal ionic currents and hyperexcitability. Psychopharmacology, 2012, Volume: 221, Issue:4 Topics: Action Potentials; Animals; Calcium Channels, L-Type; Cell Line, Tumor; Delayed Rectifier Potassium	2012
Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. Experimental neurology, 2012, Volume: 233, Issue:1 Topics: Action Potentials; Analysis of Variance; Animals; Calcimycin; Calcium; Calcium Ionophores; Capillari	2012
Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. BMC neuroscience, 2012, Apr-05, Volume: 13 Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Excitatory Amino	2012
Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. Journal of neurochemistry, 2012, Volume: 122, Issue:5 Topics: 8-Hydroxy-2'-Deoxyguanosine; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Anti-Infl	2012
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1. Cerebellum (London, England), 2013, Volume: 12, Issue:1 Topics: Amantadine; Animals; Ataxin-1; Ataxins; Buspirone; Disease Models, Animal; Dopamine Agents; Genotype	2013
The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord. Journal of neurotrauma, 2013, Feb-01, Volume: 30, Issue:3 Topics: Animals; Arachidonate 5-Lipoxygenase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cas	2013
Enhanced excitability of guinea pig inferior mesenteric ganglion neurons during and following recovery from chemical colitis. American journal of physiology. Gastrointestinal and liver physiology, 2012, Nov-01, Volume: 303, Issue:9 Topics: Acetic Acid; Action Potentials; Animals; Anthracenes; Colitis; Disease Models, Animal; Electrophysio	2012
Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model. Annals of neurology, 2013, Volume: 73, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Apomorphine; Disease Models,	2013
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Feb-01, Volume: 23, Issue:3 Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Disease Progression; Electrophysi	2003
Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Mar-01, Volume: 23, Issue:5 Topics: Amino Acid Transport System X-AG; Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modif	2003
Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Annals of neurology, 2003, Volume: 53, Issue:4 Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Axons; Calcium Channel	2003
Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience, 2003, Volume: 119, Issue:3 Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Anterior Horn Cells; Cell Death; Cerebral Cort	2003
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacology & toxicology, 2003, Volume: 93, Issue:1 Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug	2003
Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology, 2003, Volume: 48, Issue:1 Topics: Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Dizocilpine Maleate	2003
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain research, 2003, Nov-07, Volume: 989, Issue:2 Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Ex	2003
Co-treatment with riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury. Experimental neurology, 2004, Volume: 187, Issue:2 Topics: Animals; Cell Death; Cell Survival; Dendrites; Disease Models, Animal; Drug Therapy, Combination; Fe	2004
New pharmacological strategies to restore hearing and treat tinnitus. Acta oto-laryngologica, 2004, Volume: 124, Issue:4 Topics: Animals; Apoptosis; Disease Models, Animal; Hair Cells, Auditory; Hearing Loss; JNK Mitogen-Activate	2004
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. Journal of neurology, 2004, Volume: 251, Issue:9 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Drug Therapy, Combination; Humans; I	2004
Interactions between riluzole and conventional antiepileptic drugs -- a comparison of results obtained in the subthreshold method and isobolographic analysis. Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:12 Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Interactions; Electroshock; Ma	2004
Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). Journal of neural transmission (Vienna, Austria : 1996), 2005, Volume: 112, Issue:8 Topics: Animals; Biomarkers; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine and cAMP-Regulat	2005
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Experimental neurology, 2005, Volume: 194, Issue:1 Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal	2005
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiology of disease, 2006, Volume: 21, Issue:1 Topics: Animals; Benzothiazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Genotype;	2006
Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Investigative ophthalmology & visual science, 2005, Volume: 46, Issue:12 Topics: Adolescent; Animals; Animals, Newborn; Cattle; Cell Culture Techniques; Cell Proliferation; Disease	2005
Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Investigative ophthalmology & visual science, 2005, Volume: 46, Issue:12 Topics: Adolescent; Animals; Animals, Newborn; Cattle; Cell Culture Techniques; Cell Proliferation; Disease	2005
Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Investigative ophthalmology & visual science, 2005, Volume: 46, Issue:12 Topics: Adolescent; Animals; Animals, Newborn; Cattle; Cell Culture Techniques; Cell Proliferation; Disease	2005
Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Investigative ophthalmology & visual science, 2005, Volume: 46, Issue:12 Topics: Adolescent; Animals; Animals, Newborn; Cattle; Cell Culture Techniques; Cell Proliferation; Disease	2005
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Experimental neurology, 2006, Volume: 198, Issue:1 Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; CD11b Antigen; Cell Death; Choline O-Acetyl	2006
Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro. The European journal of neuroscience, 2006, Volume: 24, Issue:12 Topics: Analysis of Variance; Animals; Animals, Newborn; Cell Count; Cell Survival; Cells, Cultured; Disease	2006
A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. Journal of neurochemistry, 2007, Volume: 100, Issue:5 Topics: Amines; Analgesics; Animals; Anticonvulsants; Cold Temperature; Cyclohexanecarboxylic Acids; Disease	2007
Anti-glutamatergic effect of riluzole: comparison with valproic acid. Neuroscience, 2007, Jun-15, Volume: 147, Issue:1 Topics: Animals; Anticonvulsants; Dentate Gyrus; Disease Models, Animal; Epilepsy, Absence; Excitatory Posts	2007
Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2007, Volume: 14, Issue:7 Topics: Animals; Behavior, Animal; Disease Models, Animal; Lipid Peroxidation; Locomotion; Male; Mexiletine;	2007
Evaluation of the systemic use of riluzole in post-traumatic facial nerve regeneration: experimental study in rabbits. Acta oto-laryngologica, 2007, Volume: 127, Issue:11 Topics: Animals; Disease Models, Animal; Facial Nerve Injuries; Facial Paralysis; Follow-Up Studies; Male; N	2007
Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007, Nov-28, Volume: 27, Issue:48 Topics: Age Factors; Amyotrophic Lateral Sclerosis; Analysis of Variance; Animals; Behavior, Animal; Disease	2007
Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: inhibition by riluzole. Investigative ophthalmology & visual science, 2007, Volume: 48, Issue:12 Topics: Animals; Animals, Newborn; Blotting, Western; Dextrans; Disease Models, Animal; Enzyme-Linked Immuno	2007
Postnatal electrical and morphological abnormalities in lumbar motoneurons from transgenic mouse models of amyotrophic lateral sclerosis. Archives italiennes de biologie, 2007, Volume: 145, Issue:3-4 Topics: Action Potentials; Amyotrophic Lateral Sclerosis; Animals; Animals, Newborn; Biotin; Cell Differenti	2007
Prodystonic effects of riluzole in an animal model of idiopathic dystonia related to decreased total power in the red nucleus? European journal of pharmacology, 1997, Aug-06, Volume: 332, Issue:2 Topics: Animals; Antiparkinson Agents; Calcium Channel Blockers; Cricetinae; Disease Models, Animal; Dystoni	1997
Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology, 1998, Volume: 50, Issue:1 Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Female; Longevity; Male; Mice; Mice,	1998
Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome. Journal of neurotrauma, 1998, Volume: 15, Issue:9 Topics: Age Factors; Animals; Battered Child Syndrome; Body Temperature; Disease Models, Animal; Dose-Respon	1998
Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. European journal of pharmacology, 1998, Sep-04, Volume: 356, Issue:2-3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Behavior, Animal; Disease Mo	1998
Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology, 1998, Volume: 37, Issue:8 Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glutamic Acid;	1998
Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:3 Topics: Animals; Anticonvulsants; Disease Models, Animal; Heart Arrest; Histocytochemistry; Male; Movement D	1999
Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping. The Journal of thoracic and cardiovascular surgery, 1999, Volume: 117, Issue:5 Topics: Animals; Aorta, Abdominal; Apoptosis; Constriction; Cytoplasm; Disease Models, Animal; DNA; DNA Frag	1999
A word of caution in extrapolating the riluzole spinal cord injury protective effects obtained in a rabbit model under ketamine anesthesia. The Journal of thoracic and cardiovascular surgery, 1999, Volume: 118, Issue:6 Topics: Anesthetics, Dissociative; Animals; Cardiopulmonary Bypass; Disease Models, Animal; Drug Synergism;	1999
The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology, 2000, Apr-03, Volume: 39, Issue:6 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum;	2000
Neuroprotective effect of low dose riluzole in gerbil model of transient global ischemia. Neuroscience letters, 2000, Nov-10, Volume: 294, Issue:1 Topics: Animals; Body Temperature; Cell Count; Cell Survival; Disease Models, Animal; Dose-Response Relation	2000
Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. Anesthesiology, 2000, Volume: 93, Issue:5 Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Infarction; Ketamine; Neuroprote	2000
Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). Journal of the neurological sciences, 2000, Nov-01, Volume: 180, Issue:1-2 Topics: Animals; Body Weight; Disease Models, Animal; Hand Strength; Mice; Mice, Transgenic; Motor Neuron Di	2000
Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Callithrix; Disease Models,	2002
Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig. Neuroscience, 2002, Volume: 111, Issue:3 Topics: Acoustic Stimulation; Action Potentials; Animals; Auditory Threshold; Cell Count; Cochlea; Cochlear	2002
Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice. Experimental neurology, 2002, Volume: 176, Issue:1 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Prote	2002
Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neuroscience letters, 1992, Jun-22, Volume: 140, Issue:2 Topics: Animals; Brain Ischemia; Disease Models, Animal; Electroencephalography; Gerbillinae; Ischemic Attac	1992
Anticonvulsant and sleep-waking influences of riluzole in a rat model of absence epilepsy. European journal of pharmacology, 1991, Jul-09, Volume: 199, Issue:3 Topics: Animals; Anticonvulsants; Cerebral Cortex; Circadian Rhythm; Disease Models, Animal; Electromyograph	1991

riluzole and Disease Models, Animal